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SYSTEMATIC REVIEW AND META-ANALYSIS
Outcomes of Atrial Arrhythmia Surgery in 
Patients With Congenital Heart Disease:  
A Systematic Review
Charlotte A. Houck, MD; Natasja M. S. de Groot , MD, PhD; Isabella Kardys, MD, PhD; Christa D. Niehot, BS; 
Ad J. J. C. Bogers, MD, PhD; Elisabeth M. J. P. Mouws , MD, PhD
BACKGROUND: The improved life expectancy of patients with congenital heart disease is often accompanied by the develop-
ment of atrial tachyarrhythmias. Similarly, the number of patients requiring redo operations is expected to continue to rise as 
these patients are aging. Consequently, the role of arrhythmia surgery in the treatment of atrial arrhythmias is likely to become 
more important in this population. Although atrial arrhythmia surgery is a well-established part of Fontan conversion proce-
dures, evidence-based recommendations for arrhythmia surgery for macroreentrant atrial tachycardia and atrial fibrillation in 
other patients with congenital heart disease are still lacking.
METHODS AND RESULTS: Twenty-eight studies were included in this systematic review. The median reported arrhythmia re-
currence was 13% (interquartile range, 4%–26%) during follow-up ranging from 3 months to 15.2 years. A large variation in 
surgical techniques was observed. Based on the acquired data, biatrial lesions are more effective in the treatment of atrial 
fibrillation than exclusive right-sided lesions. Right-sided lesions may be more appropriate in the treatment of macroreentrant 
atrial tachycardia; evidence for the superiority of additional left-sided lesions is lacking. There are not enough data to support 
the use of exclusive left-sided lesions. Theoretically, prophylactic atrial arrhythmia surgery may be beneficial in this population, 
but evidence is currently limited.
CONCLUSIONS: To be able to provide recommendations for arrhythmia surgery in patients with congenital heart disease, future 
studies should report outcomes according to the type of preoperative arrhythmia, underlying congenital heart disease, lesion 
set, and energy source. This is essential for determining which surgical techniques should ideally be applied under which 
circumstances.
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Congenital heart disease (CHD) is the most com-mon cause of congenital anomalies, with an es-timated prevalence of 9 per 1000 live births and 
4 per 1000 adults.1,2 Although surgical correction or 
palliation is often performed in childhood, a consider-
able number of patients (20%) require primary or redo 
surgery in adulthood.3,4 As a result of improved life ex-
pectancy in these patients, the number of redo opera-
tions is expected to continue to rise. Patients may not 
only require redo operations for their primary defect, 
but also for acquired coronary or valvular heart dis-
ease.5,6 Moreover, the improved life expectancy in CHD 
patients is often accompanied by the development of 
atrial tachyarrhythmia (ATA), including macroreentrant 
atrial tachycardia (MRAT) and atrial fibrillation (AF).7,8 
ATAs in this population occur at a relatively young 
age and show rapid progression, resulting in impaired 
quality-of-life, morbidity, and mortality.8–10
Therefore, the role of arrhythmia surgery in the 
treatment of atrial arrhythmias may become more 
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important in this specific population. For patients 
undergoing Fontan conversion, class I recommen-
dations were provided by the 2014 Pediatric and 
Congenital Electrophysiology Society (PACES)/
Heart Rhythm Society (HRS) guidelines in favor of 
performing concomitant atrial arrhythmia surgery, 
which is supported by a large body of evidence.11 
However, on atrial arrhythmia surgery in other pa-
tients with CHD, recommendations provided by 
multiple guidelines are either largely extrapolated 
from studies on patients without CHD,11 patients un-
dergoing Fontan conversion,12 or they are based on 
only a small number of published studies in this pop-
ulation.12,13 In addition, the 2017 Society of Thoracic 
Surgeons guidelines for surgical treatment of AF do 
not yet provide specific recommendations for pa-
tients with CHD at all.14
Therefore, this systematic review aimed to evaluate 
and summarize outcomes of atrial arrhythmia surgery 
for MRAT and AF in patients with CHD undergoing car-
diac surgery other than Fontan conversion.
METHODS
The systematic review was performed in accord-
ance with the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) guidelines.15 
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Search Strategy and Selection Criteria
We searched Embase, MEDLINE, Web-of-Science 
Core Collection, Cochrane Library, and Google 
Scholar for relevant articles using terms associated 
with congenital heart disease and atrial arrhythmia 
surgery up to November 20, 2019, with no start date 
restriction. The complete search strategy is pro-
vided in Data S1. Additionally, we manually searched 
reference lists of identified articles and relevant 
reviews.
Eligibility assessment of identified articles was 
performed independently by 2 reviewers (C. H., E. M.); 
disagreements were resolved by consensus. Studies 
were first screened based on title and abstract. If po-
tentially relevant, the full text was assessed. Studies 
were included if they reported outcomes of arrhyth-
mia surgery for AF or MRAT in patients with CHD 
undergoing surgery other than Fontan conversion. 
Studies were excluded if they only reported outcomes 
of arrhythmia surgery for focal atrial tachycardia, ac-
cessory pathways, or atrioventricular nodal reentry 
tachycardia; if duration of follow-up was <3 months; 
or if >25% of the study population consisted of pa-
tients undergoing Fontan conversion surgery. We 
excluded review articles, book chapters, conference 
abstracts, editorials, case reports, and studies writ-
ten in languages other than English. If double report-
ing of the same patient populations was suspected, 
the most recent publication was included. Both pub-
lications were included if it was possible to exclude 
duplicate data from 1 of the publications, or if both 
publications also included a substantial amount of 
unique data.
CLINICAL PERSPECTIVE
What Is New?
• Concrete, evidence-based recommendations 
for arrhythmia surgery for atrial fibrillation or 
macroreentrant atrial tachycardia in patients 
with congenital heart disease—other than those 
undergoing Fontan conversion—are currently 
lacking.
• This systematic review, including 28 studies 
published over a time span of 25  years, pro-
vides an overview of the striking variation in sur-
gical techniques applied over the past decades.
• Outcomes of arrhythmia recurrence and ad-
verse events, such as new-onset atrial tach-
yarrhythmias and permanent pacemaker 
implantation, are summarized.
What Are the Clinical Implications?
• Based on the acquired data, biatrial lesions are 
preferred in the treatment of atrial fibrillation, 
whereas exclusive right-sided lesions are likely 
more appropriate in the treatment of macro-
reentrant atrial tachycardias.
• Evidence supporting prophylactic atrial ar-
rhythmia surgery is currently limited, and find-
ings from this review emphasize the need for 
uniformity of surgical techniques in this unique 
population.
• To be able to determine which surgical tech-
niques should ideally be applied under which 
circumstances, detailed documentation of 
methodology (indication, underlying congenital 
heart defect, lesion set, and energy source) in 
future studies is essential.
Nonstandard Abbreviations and Acronyms
AAD anti-arrhythmic drugs
ATA atrial tachyarrhythmias
MRAT macroreentrant atrial tachycardia
SND sinus node dysfunction
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Data Extraction and Data Appraisal
Data extraction was performed by 1 reviewer (C. H.) 
into a predetermined template and the extracted data 
were subsequently checked for accuracy by the sec-
ond reviewer (E. M.). Disagreements were resolved 
by discussion and where necessary, a third reviewer 
with expertise in the field (A. B.) was consulted.
Available data on study characteristics (study pe-
riod, study design), patient characteristics (age, sex, 
CHD type, preoperative arrhythmias), procedural 
characteristics (location of lesions, energy source) 
and follow-up (duration, arrhythmia recurrence, 
new-onset ATA, permanent pacemaker implanta-
tion) were collected. The number of arrhythmia re-
currences was derived from Kaplan-Meier curves, 
where possible, if it was not explicitly described. If 
a distinction was made between early (generally 
<3 months) and late recurrences, the number of late 
recurrences was selected.
Quality assessment of the included articles was 
performed using the Newcastle-Ottawa Scale (non-
randomized studies) or the Cochrane Risk of Bias 2 
tool (randomized controlled trials).16,17 The Newcastle 
Ottawa Scale assesses risk of bias and ranges from 
0 points (high risk) to 9 points (low risk). The follow-
ing items were assessed: (1) representativeness of the 
exposed cohort (1 point), (2) selection of the non-ex-
posed cohort (1 point), (3) ascertainment of exposure 
(ie, arrhythmia surgery) (1 point), (4) demonstration that 
the outcome of interest was not present at the start 
of the study (1 point), (5) comparability of cohorts on 
the basis of the design or analysis (2 points), (6) as-
sessment of outcome (1 point), (7) follow-up being long 
enough (ie, mean/median >6 months) for outcomes to 
occur (1 point), and (8) adequacy of follow-up of co-
horts (1 point). The Risk of Bias 2 tool assesses risk of 
bias in 5 domains: randomization process, deviations 
from the intended intervention, missing outcome data, 
measurement of the outcome, and selection of the re-
ported result.
Data Analysis
Outcomes of arrhythmia surgery were presented for 
relevant subcategories (type of arrhythmia surgery or 
CHD). When calculating the proportion of patients with 
a recurrence, the preferred denominator was the num-
ber of patients who had long-term follow-up available 
(excluding early deaths and those lost to follow-up); 
otherwise, the number of patients at the start of the 
study was used. The 95% CI was calculated using the 
normal approximation method; when conditions were 
not appropriate for approximation of the binomial dis-
tribution by the normal distribution, a Clopper-Pearson 
interval was calculated.18 Pronounced heterogene-
ity within and between studies (eg, large variation 
in follow-up duration) precluded meaningful meta-
analyses, even after dividing the studies into relevant 
subcategories.19 To provide an overall indication of 
the outcomes of the studies anyhow, the median (in-
terquartile range [IQR]) was provided for the following 
parameters: duration of inclusion period, quality score, 
and the number of arrhythmia recurrences or perma-
nent pacemaker implantations.
RESULTS
As illustrated in Figure 1, our initial search identified 
2175 records after removal of duplicates and addi-
tion of 1 article identified by searching reference lists. 
After exclusion of records based on screening of title 
and abstract, 132 full-text articles were assessed 
for eligibility, resulting in 28 studies included in this 
review.20–47
A summary of the included studies is provided in 
Table 1. Of the included studies, 27 were cohort stud-
ies and 1 was a randomized controlled trial. First of all, 
quality of the included studies as assessed by the 
Newcastle-Ottawa Scale was relatively good. As we 
only included data from patients (cases) and not from 
controls (where applicable), items (2) and (5) of the 
scale were not assessed, resulting in a maximum score 
of 6 points. The median score was 5 (IQR 5–6). Most 
scores <6 were because of the lack of information with 
regard to follow-up duration or loss to follow-up if the 
study population of interest was a subset of a larger 
group of patients.* In some cases, follow-up was 
short,35 loss to follow-up was relatively high,23 or the 
authors did not provide specific information about pa-
tient acquisition34 or the objective assessment of 
rhythm outcomes.25,27,46 The randomized controlled 
trial was judged to be at low risk for bias in all 5 
domains.
Year of publication ranged from 1994 to 2019 (me-
dian 2010) and patients were included over a median 
span of 10  years (IQR, 4–17). Overall, the reported 
number of ATA recurrences during variable follow-up 
periods ranged between 0% and 78% (median 13%, 
IQR, 4%–26%; Table 1). Potentially duplicate data were 
presented in 4 studies29,42–44; the decision to include 
these studies was based on the presence of a signifi-
cant amount of unique data in each study according to 
the inclusion period and inclusion criteria.
Types of Arrhythmia Surgery
Most studies provided a comprehensive description 
of their methods for arrhythmia surgery (n=18, 64%),† 
which was accompanied by a detailed figure of 
*References 21, 25, 28, 31, 36, 38, 42, 45, 47.
†References 20–23, 25–27, 29–35, 38, 40, 41, 46.
D
ow
nloaded from
 http://ahajournals.org by on N
ovem
ber 18, 2020
J Am Heart Assoc. 2020;9:e016921. DOI: 10.1161/JAHA.120.016921 4
Houck et al Arrhythmia Surgery in Congenital Heart Disease
lesion sets and/or references in 14 studies.‡ Six stud-
ies described their method only by referring to a pre-
viously published study providing a comprehensive 
description,24,28,36,42,43,45 and in 4 studies, the method 
applied was referred to only by name.37,39,44,47 The 
studies demonstrated a large variation in methods 
used for arrhythmia surgery, including the locations 
of lesions within the atria and the use of different en-
ergy sources. Not only did these methods vary be-
tween studies, but also between patients within 
studies.
Biatrial Arrhythmia Surgery
Biatrial arrhythmia surgery, consisting of lesions in 
both the right and left atrium, was performed in 19 
studies (68%) (Table 1), including 10 studies in which 
biatrial lesions were applied in >20 patients. Lesions 
were generally applied according to the Cox Maze III/
IV lesion set, sometimes with modifications.48,49 Four 
studies only performed isolation of the pulmonary 
veins instead of the full left atrial lesion set in a sub-
set of patients. Specific outcomes for these varia-
tions were only provided in the study by Sakamoto 
et al, who showed similar outcomes for the full left 
atrial lesion set versus exclusive isolation of the pul-
monary veins in the context of biatrial arrhythmia sur-
gery (P=0.70).37,39,40,44 In most studies (n=16), biatrial 
arrhythmia surgery was performed in patients with 
AF; the 3 other studies did not specify the type of 
preoperative arrhythmia.24,39,44
Fourteen of the 19 studies provided separate out-
comes of biatrial arrhythmia surgery, which are sum-
marized in the upper panel of Figure 2. The number 
of arrhythmia recurrences reported in these studies 
varied between 0% and 78% (median, 13%; IQR, 0%–
27%), during follow-up ranging from 0.4 to 7.4 years. 
Even though sample sizes of studies published from 
2013 onwards were larger than those of earlier stud-
ies, 95% CIs were still relatively wide, spanning a range 
of ≈20%. When only considering the 8 studies with 
sample size >20, the median reported amount of ar-
rhythmia recurrences was 20% (IQR, 11%–39%) during 
follow-up ranging from 1 to 7.4 years.‡References 20, 22, 23, 25–27, 29–31, 33–35, 38, 40.
Figure 1. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the study selection.
CHD indicates congenital heart disease.
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Interestingly, 1 study reported outcomes of biatrial 
arrhythmia surgery according to type of preoperative 
AF and found no difference in the number of recur-
rences between patients with paroxysmal AF and 
those with non-paroxysmal AF (45% versus 44%; P 
values not provided).40 Also, the presence of CHD 
did not appear to influence the results of biatrial ar-
rhythmia surgery in the study of Engelsgaard et al. 
In their study, they reported outcomes of the Cox 
maze IV procedure for AF in 144 patients, including 
41 patients with CHD, during a median follow-up of 
7.4  years (IQR, 2.7).21 Despite their strict definition 
of recurrent arrhythmias (>3  months after the pro-
cedure, lasting ≥30 seconds, documented on ECG, 
Holter monitoring, or device interrogations), a rela-
tively high number of recurrences was observed in 
both patients without CHD (79%) and patients with 
CHD (78%; P value not provided).
Right-Sided Arrhythmia Surgery
Exclusive right-sided arrhythmia surgery was per-
formed in 19 studies (68%) (Table 1). In the majority of 
these studies (n=11), lesions were generally applied 
Figure 2. Outcomes of biatrial arrhythmia surgery (upper panel) and right-sided arrhythmia surgery (lower panel).
Forest plot of the proportions of patients with arrhythmia recurrence and corresponding 95% CIs. The overall median and interquartile 
range of proportions are displayed in red. AF/MRAT indicates that both arrhythmias were regarded as indication: outcomes of 
arrhythmia surgery were not further specified according to the type of preoperative arrhythmia. AR indicates atrial fibrillation; IQR, 
interquartile range; and MRAT, macroreentrant atrial tachycardia; *Outcome measure: recurrence of preoperative arrhythmia or other 
atrial tachyarrhythmias (not specified). †Outcome measure: recurrence or on anti-arrhythmic drugs. ‡Partially duplicate data but 
studies also contain a significant amount of unique data. §Including n=22 patients with exclusive isthmus ablation; outcomes not 
specified. ||Including n=9 patients with exclusive isthmus ablation; outcomes specified in text. #Right atrial compartment or isolation 
techniques applied. **Number of patients at start of study. ¤Separate outcomes only available in sub-analysis at 1 year follow-up. 
»Follow-up not specified for subgroup.
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according to the right-sided maze procedure,§ which 
is a modification of the traditional Cox maze III proce-
dure. This modification was proposed and published 
in 1998 and was specifically intended for patients with 
CHD affecting the right side of the heart.50 Several 
older studies used the right atrial compartment or iso-
lation technique, which generally consisted of a single 
incision parallel to the sulcus terminalis, extending 
posteriorly and anteriorly towards the tricuspid valve 
annulus, including cryolesions between the incision 
and the tricuspid valve.25,34,46 Solely cryoablation of 
the cavotricuspid isthmus was performed in 3 stud-
ies.25,28,29 The indication for right-sided arrhythmia 
surgery was AF (n=626,30,34,42,46,47), MRAT (n=136) or 
both (n=922–25,28,29,39,43,44). Three studies performed 
prophylactic right-sided arrhythmia surgery.20,33,35
Twelve of the 19 studies provided separate results 
of right-sided arrhythmia surgery in patients with AF 
or MRAT (lower panel Figure 2). The proportion of ar-
rhythmia recurrences was below 30% in most studies 
(median 19%, IQR 7–29%) during follow-up ranging 
from 1 to 13.2 years. Studies performed before 2004 
had smaller sample sizes resulting in more imprecise 
estimates of true arrhythmia recurrence. The 2 studies 
reporting the highest proportion of arrhythmia recur-
rence (50% and 100%) had only small study popula-
tions (respectively n=234 and n=330).
Separate outcomes of the right-sided maze proce-
dure versus exclusive cyroablation of the isthmus were 
provided in the study of Khositseth et al. In patients 
undergoing surgery for Ebstein anomaly, they found 
no significant difference in the recurrence rate be-
tween the 2 procedures (10/35 [29%] versus 1/9 [11%], 
P=0.50), although the type of preoperative arrhythmia 
(AF or MRAT) was not specified.29 Outcomes of the 
right-sided maze procedure according to the type of 
preoperative arrhythmia were reported in the study of 
Stulak et al: though not statistically significant, arrhyth-
mias appeared to recur more often when the indica-
tion was AF (6/62 [10%]) rather than MRAT (0/21 [0%], 
P value not provided) and when the indication was 
non-paroxysmal AF (3/11 [27%]) rather than paroxys-
mal AF (3/51 [6%], P=0.15).43
Biatrial Versus Right-Sided Arrhythmia Surgery
Three studies performed both biatrial and right-sided 
arrhythmia surgery for similar indications in their 
study population and reported separate outcomes 
for each procedure.26,30,44 When comparing biatrial 
and exclusive right-sided lesions for the treatment 
of AF in patients with an atrial septal defect (ASD), 
2 studies showed that exclusive right-sided lesions 
appeared to be less effective than biatrial lesions 
(recurrence right versus biatrial: 7/23 [30%] versus 
3/33 [9%]26 and 3/3 [100%] versus 0/23 [0%]).30 In 
addition, exclusive right-sided lesions appeared to 
be less effective than biatrial lesions in the treatment 
of non-paroxysmal AF/MRAT (recurrence right ver-
sus biatrial: 7/19 [37%] versus 3/29 [10%]26 and 29% 
versus 14% [P=0.053]),44 whereas the number of re-
currences in patients with paroxysmal AF/MRAT was 
fairly similar for both lesion sets (recurrence right ver-
sus biatrial: 0/4 [0%] versus 0/4 [0%]26 and 12% ver-
sus 23% [P=0.08]).44 In line with these observations, 
authors of several studies explicitly state that their 
current policy—which is in contrast to that during the 
study period in some cases—is to perform biatrial 
arrhythmia surgery in patients with AF (regardless of 
duration) or longstanding ATA, also in patients with 
predominantly right-sided CHD.22,26,37,44
Left-Sided Arrhythmia Surgery
Only 5 studies (18%) performed exclusive left-sided 
arrhythmia surgery in a relatively small subset of 
their study populations (median, 5%; IQR, 4%–40%; 
Table 1). None of these studies provided solid indica-
tions for performing exclusively left-sided rather than 
biatrial arrhythmia surgery and none provided separate 
results on the outcomes of exclusively left-sided ar-
rhythmia surgery. Two studies performed isolated pul-
monary vein isolation in only a small subset of patients 
(2/1037 and 5/6639), but they did not report outcomes 
in these patients.
Energy Sources
The original Cox Maze III procedure consists of a set of 
atrial incisions (also called “the cut-and-sew technique”) 
which makes it a technically complex and long proce-
dure, with a relatively high incidence of postoperative 
bleeding.48,49,51 Over the years, various alternative en-
ergy sources have been used in an attempt to simplify 
the technique, which also applies to the studies included 
in this review. Most studies published up until 2007 (9 of 
12) used a combination of incisions and cryolesions. ‖ 
The other 3 studies only used cryoablation.29,35,38 The 
first study included in this review to report the use of ra-
diofrequency energy is that of Lai et al.32 Nine of the 15 
studies published thereafter used radiofrequency en-
ergy.21,22,37,39–42,44,47 None of the studies compared out-
comes of different types of energy sources.
Prophylactic Arrhythmia Surgery
As shown in Table  2, 4 studies described out-
comes of prophylactic arrhythmia surgery in patients 
with CHD undergoing surgery other than Fontan 
§References 22–24, 26, 30, 36, 39, 42–44, 47.  ‖ References 25, 27, 28, 30, 31, 34, 43, 45, 46.
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conversion.20,23,33,35 One study only provided the 
general location of the lesions (right-sided or biatrial), 
whereas the other 3 applied a standardized lesion or 
lesion set, which included a lesion between the right 
atriotomy and the right atrioventricular valve annulus in 
all. The randomized controlled trial of Atallah et al was 
not able to detect differences in terms of efficacy or 
safety between the intervention and control group, al-
though sample size was small and follow-up may not 
have been long enough to detect late occurrence of 
MRAT. Prophylactic arrhythmia surgery in the study 
of Lim et al included 2 additional lesions and modi-
fications of suture lines; 4 cases of spontaneous (1) 
and inducible non-sustained MRAT (3) were observed 
during long-term follow-up.20 Interestingly, the 4 cases 
of atrial flutter (either spontaneous or induced) in the 
study of Lukac et al35 occurred in the 4 patients in 
whom bidirectional block was not obtained because 
of incomplete cryolesions, thereby creating an isth-
mus between the atriotomy scar and the tricuspid 
annulus and facilitating the development of reentry 
tachycardias. This led the authors to conclude that, al-
though effective when bidirectional block is achieved, 
this prophylactic lesion may be proarrhythmogenic in 
the absence of bidirectional block.
Anti-Arrhythmic Drugs
Table  3 provides an overview of available data 
on perioperative use of anti-arrhythmic drugs (AAD). 
Twelve studies (39%) provided information on their 
policy on postoperative AAD use. These policies were 
more or less in accordance with the 2017 guidelines 
for surgical treatment of AF, which advise the use 
of a class III AAD, eg, amiodarone, for at least 2 to 
3  months after surgery until stable sinus rhythm is 
achieved.14 However, several studies only prescribed 
AAD in case of early postoperative AF. Thirteen studies 
(46%) specified the number of patients using periop-
erative AAD, which varied considerably: preoperative 
AAD use ranged from 35% to 100% and postopera-
tive AAD use from 0% to 83%. Two studies reported 
a substantial decrease in the number of patients using 
AAD after arrhythmia surgery,22,43 whereas use of AAD 
remained stable or showed only a minimal decrease 
in 3 studies.23,24,39 Data comparing the use of AAD in 
patients with or without arrhythmia recurrence were 
reported in 2 studies (54% versus 30%, P=0.0424 and 
81% versus 79%, P value not available39).
Outcomes According to Type of 
Congenital Heart Disease
As summarized in Table  1, a considerable number 
of studies reported outcomes of arrhythmia surgery 
in a cohort of patients with a variety of CHD. CHD-
specific outcomes were provided in 12 studies for 
patients with an ASD, in 4 studies for patients with 
Ebstein anomaly, and in 1 study for patients with te-
tralogy of Fallot.
Atrial Septal Defect
Most studies (n=8) performed biatrial arrhythmia sur-
gery in patients with an ASD, 4 studies performed 
right-sided arrhythmia surgery and 2 did not spec-
ify outcomes according to the location of lesions 
(Figure 3). As described before, 2 studies compared 
outcomes after biatrial versus right-sided arrhythmia 
surgery for AF in patients with ASD, and showed 
that biatrial lesions were more effective.26,30 Overall, 
as illustrated in Figure 3, the reported proportion of 
arrhythmia recurrence after biatrial arrhythmia sur-
gery (median, 5%; IQR, 0%–30%, follow-up range, 
0.4–7  years) appeared to be somewhat smaller 
than after right-sided arrhythmia surgery (median, 
40%; IQR, 17%–88%, follow-up range, 2–4.1 years). 
However, this should be interpreted with great cau-
tion as 95% CIs of the proportions in a considerable 
number of studies were wide.
Table 2. Prophylactic Arrhythmia Surgery
Author, y No. CHD Lesions Outcome
Gonzalez Corcia et al, 201923 29 Mainly Ebstein Right-sided lesions*: 28 
Biatrial lesions*: 1
Freedom from ATA at 1, 3, 5 y: 97%, 97%, 
80%
Lim et al, 201733 27 Initial LT Fontan 1. Atrial incision right atriotomy – CS
2. Cryolesion right atriotomy—RAVV
3. Sandwich closure right atriotomy
Spontaneous MRAT: 1/27 (3.7%) at 12.6 y 
Inducible non-sustained MRAT, 3/19 (11.1%) at 
5.2 to 11.8 y
Atallah et al, 201220 15 Initial LT Fontan Atrial incision right atriotomy—RAVV Spontaneous MRAT, 0/15 (0%) at 9 y 
Inducible MRAT, 0/2 (0%) at 9 y
14 Initial LT Fontan Control group (no prophylactic 
lesion)
Spontaneous MRAT, 0/14 (0%) at 9.3 y 
Inducible MRAT, 0/5 (0%) at 9.3 y
Lukac et al, 200735 17 Mainly ASD Cryolesion right atriotomy—RAVV Spontaneous MRAT, 2/17 (12%) at 3 mo 
Inducible MRAT, 2/17 (12%) at 3 mo
ASD indicates atrial septal defect; ATA, atrial tachyarrhythmias; CHD, congenital heart disease; CS, coronary sinus; LT, lateral tunnel; MRAT, macroreentrant 
atrial tachycardia; and RAVV, right atrioventricular valve.
*Lesion locations and energy sources not further specified.
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Two studies demonstrated the positive effect of 
concomitant arrhythmia surgery on the occurrence 
of postoperative AF when compared with ASD repair 
only. In the study of Kobayashi et al, 26 patients with 
a history of AF underwent ASD repair and concom-
itant arrhythmia surgery; AF persisted after surgery 
Table 3. Anti-Arrhythmic Drugs
Author, y
Postoperative AAD Policy 
(Indication, Duration, Class) Preoperative AAD Use Postoperative AAD Use
Sakamoto et al, 201940 All patients, max. 3 mo, AAD class N/A … …
Gonzalez Corcia et al, 201923 … Class I, III*: 
24/77 without recurrence 
11/24 with recurrence
Class I, III*: 
23/77 without recurrence 
13/24 with recurrence
Ramdjan and Mouws 201839 … Class I to IV, digoxin: 
MRAT, 5/6 
AF, 58/60
Class I to IV, digoxin: 
MRAT, N/A 
AF, 50/60 
27/33 without recurrence 
23/27 with recurrence
Engelsgaard et al, 201821 All patients, at least early postoperative, 
AAD class N/A
… …
Lim et al, 201733 … … Class II, 
2/27
Giamberti et al, 201722 All patients, at least 3 mo, AAD class III 
(amiodarone)
AAD class N/A 
51/80
AAD class N/A 
12/75
Stulak et al, 201544 AF, 3 mo, AAD class III … …
Wi et al, 201347 … … Class I/III: 
PAF, : 0/3 
PeAF, 5/12 without recurrence
Shim et al, 201341 AF, duration N/A 
AAD class III (amiodarone)
… …
Nitta et al, 201337 … … …
Im et al,201326 AF, AAD class I/III 3 mo, digoxin >3 mo … …
Gutierrez et al, 201324 … Class I, III: 8/19 
Class II, digoxin: 16/19
Class I, III: 4/19 
Class II, digoxin: 13/19
Stulak et al, 201242 … … …
Atallah et al, 201220 … … …
Mavroudis et al, 200836 … … …
Lai et al, 200832 All patients, max. 3 mo, AAD class III 
(amiodarone)
… 0/7
Lukac et al, 200735 … … Class I, III: 0/17 
Class II, digoxin: 1/17
Stulak et al, 200643 AF, 3 mo, AAD class III Cardiac medications: 77/99 
Class II: 22% 
Class III (amiodarone): 15% 
Digoxin: 42%
Class I: 1/87 
Class II: 12/87 
Class III (amiodarone): 8/87 
Class IV: 1/87 
Digoxin: 24/87
Karamlou et al, 200628 … … …
Ohtsuka et al, 200538 All patients, duration N/A, digoxin … …
Khositseth et al, 200429 … … RSM, 4/35 AAD class N/A 
CTI, 1/9 AAD class III (amiodarone)
Huang et al, 200025 … … …
Kobayashi et al, 199830 … … …
Kamata et al, 199727 … … …
Vigano et al, 199646 All patients, duration N/A, AAD class III 
(amiodarone)
… Class III (amiodarone): 1/7
Lin et al, 199634 … Class I, digoxin: 1/2 0/2
Kosakai et al, 199531 All patients, until stable SR, AAD class N/A … …
Suwalski et al, 199445 All patients, 3 mo, AAD class II Class I to IV, digoxin: 3/3 …
AAD indicates anti-arrhythmic drugs; AF, atrial fibrillation; CTI, exclusive cavotricuspid isthmus ablation; MRAT, macroreentrant atrial tachycardia; PAF, 
paroxysmal atrial fibrillation; PeAF, persistent atrial fibrillation; RSM, right-sided maze; and SR, sinus rhythm.
*Outcomes from sub-analysis at 1-year follow-up. 
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in 3 patients (12%). However, postoperative AF oc-
curred less often in the 23 patients who regained 
sinus rhythm after arrhythmia surgery (0/23, 0%) than 
in patients without a history of AF who only under-
went ASD repair (8/45, 18%).30 In patients with pre-
operative non-paroxysmal AF, Wi et al showed that 
the prevalence of postoperative AF was higher in 
those undergoing ASD repair only (14/17, 82%) than 
in those undergoing concomitant arrhythmia surgery 
(3/12, 25%, P=0.006).47
Ebstein Anomaly
As displayed in Table 1, 4 studies provided separate 
outcomes of atrial arrhythmia surgery in patients with 
Ebstein anomaly, who are particularly at risk of devel-
oping ATA because of their often severely enlarged 
right atrium.25,29,31,44 Of note, the 2 largest studies 
of these 4 were performed in the same center and 
their inclusion period showed an overlap of 6 years 
(1995–2001); hence, duplicate data may be present 
in these studies.29,44 However, both studies also 
provide unique data for parts of their inclusion pe-
riods that lasted 5 years (1990–199529) and 11 years 
(2001–201244) respectively. In the initial study, 48 
patients underwent right-sided arrhythmia surgery 
(right-sided maze procedure: 38, isthmus ablation: 
10), resulting in an overall freedom from recurrent ATA 
of 74.6%±7.1% during a mean follow-up of 2.8 years. 
In the more recent study, 86 patients underwent ei-
ther right-sided (n=62) or biatrial arrhythmia surgery 
(n=24), resulting in an overall freedom from recurrent 
ATA of 91% during a median follow-up of 4.5 years. 
As described before, biatrial lesions were more effec-
tive than right-sided lesions in the treatment of non-
paroxysmal ATA in these patients. In the 2 smaller 
studies, either right-sided or biatrial arrhythmia sur-
gery was performed. Both studies reported no re-
currence of ATA in any of the patients (0/3 at mean 
follow-up of 13.2 years25 and 0/1 at mean follow-up 
of 1.9 years31).
Tetralogy of Fallot
Only 1 study documented the prevalence of arrhyth-
mias in 249 patients with tetralogy of Fallot undergoing 
reoperation and evaluated the outcomes of arrhythmia 
surgery in a subset of these patients.28 Their results 
showed great advantage of performing arrhythmia 
surgery in those with documented preoperative ar-
rhythmias. ATA were present before surgery in 41/249 
(16%) patients, and 34 of these patients underwent 
Figure 3. Outcomes of arrhythmia surgery in patients with an atrial septal defect.
Forest plot of the proportions of patients with arrhythmia recurrence and corresponding 95% CIs. The overall median and interquartile 
range of proportions are displayed in red. IQR indicates interquartile range. *Outcome measure: recurrence of preoperative arrhythmia 
or other atrial tachyarrhythmias (not specified). †Right atrial compartment or isolation techniques applied. ‡Number of patients at start 
of study. § Follow-up not specified for subgroup.D
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concomitant right-sided arrhythmia surgery (isthmus 
ablation: 22, right-sided maze procedure: 12). The 7.5-
year survival free of recurrent ATA was 75% in patients 
undergoing arrhythmia surgery, as opposed to 34% of 
the 7 patients without concomitant arrhythmia inter-
vention (P<0.001).
Factors Associated With Atrial Arrhythmia 
Recurrence
As shown in Table 4, several studies analyzed the effect 
of clinical and surgical characteristics on the outcomes 
of atrial arrhythmia surgery. Independent predictors of 
arrhythmia recurrence included older age at the time of 
surgery23,39,40 and preoperative atrial arrhythmia dura-
tion ≥3 years.22 One study analyzed factors associated 
with time-to-event (event being the first episode of AF 
recurrence, new-onset ATA, or permanent pacemaker 
implantation), which was decreased in patients un-
dergoing right-sided maze procedure (versus biatrial 
arrhythmia surgery) and those with significant preop-
erative tricuspid regurgitation.26
New-Onset Atrial Tachyarrhythmia After 
Arrhythmia Surgery
Three studies reported on the development of new-
onset regular ATA after arrhythmia surgery, which may 
arise as a result of incomplete lesions. Two studies re-
ported a relatively high prevalence of new-onset reg-
ular ATA of, respectively 20% and 24% after 3.8 and 
2 years of follow-up in patients who had AF before ar-
rhythmia surgery.39,47 One of these studies even dem-
onstrated that the prevalence of new-onset ATA was 
higher in patients with arrhythmia surgery (20%) than in 
those without (8%; P value not provided).47 In addition, 
Lukac et al investigated the outcome of prophylactic 
cryolesions between the right atriotomy and the tricus-
pid annulus. In their study, new-onset spontaneous or 
inducible atrial flutter was observed in patients without 
bidirectional block within 3  months after arrhythmia 
surgery.35 Hence, this study supports the hypothesis 
of incomplete lesions as a potential cause of the de-
velopment of new-onset regular ATA after arrhythmia 
surgery.
Permanent Pacemaker Implantation
As displayed in Figure 4, 20 studies (71%) reported the 
number of patients requiring permanent pacemaker 
implantation, which varied between 0% and 42% (me-
dian, 9.6%; IQR, 0%–20%) during follow-up ranging 
from 0.3 to 15.2 years. When only considering the 13 
studies with sample size >20 patients, the median re-
ported number of pacemaker implantations increased 
to 15% (IQR, 3%–28%) during follow-up ranging from 
1 to 15.2 years.
Only 9 studies provided indications for pacemaker 
implantation, which was sinus node dysfunction (SND) 
in most cases. In 6 studies, the number of permanent 
pacemakers implanted included those implanted intra-
operatively. Indications for intraoperative pacemaker 
implantation were atrioventricular conduction block or 
sinus node dysfunction,24,33,43 or implantation as part 
of the Fontan conversion procedure (<25% of the pop-
ulation).22–24,43 In 3 studies, the indications of some or 
all intraoperative pacemaker implantations were not 
provided (23/23,36 2/22,22 unknown proportion of 3423).
DISCUSSION
Summary of Evidence
In this systematic review, we aimed to evaluate the 
outcomes of arrhythmia surgery for MRAT and AF in 
patients with CHD undergoing cardiac surgery other 
than Fontan conversion. The variation in lesion sets 
and energy sources used was striking, an observation 
Table 4. Factors Associated With Arrhythmia Recurrence
Author, y Variable Outcome HR (95% CI)
Sakamoto et al, 201940 Age at surgery Recurrence 1.067 (1.001–1.137) 
P=0.04
Gonzalez Corcia et al, 201923 Age at surgery Recurrence N/A 
P=0.0018
Ramdjan and Mouws, 201839 Age at surgery Recurrence 1.05 (1.015–1.092)* 
P=0.0006
Giamberti et al, 201722 Duration ATA ≥3 y Recurrence 11.95 (2.6–52) 
P=0.001
Im et al, 201326 1. Right-sided maze†
2. Significant TR
Time-to-event‡ 1. 5.11 (1.59–16.44) 
P=0.006 
2. 4.67 (1.38–15.87) 
P=0.014
ATA indicates atrial tachyarrhythmia; HR, hazard ratio; N/A, not available; and TR, tricuspid regurgitation.
*Odds ratio.
†vs biatrial maze.
‡Event: recurrence, new-onset atrial tachyarrhythmia, permanent pacemaker implantation.
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that was appropriately captured by Gonzalez Corcia 
et al: “Over time, ‘maze’ has become synonymous 
with just about any lesion that is applied to the atria 
as therapy for arrhythmias.”23 Not only did surgical 
techniques vary between studies, but the indications 
for which specific procedures were performed also 
differed. Even though these significant variations pre-
cluded any meaningful meta-analyses, the following 
conclusions can be drawn from the qualitative syn-
thesis of the data.
Based on the available data included in this re-
view, we can conclude that the creation of biatrial 
lesions (rather than exclusive right-sided lesions) is 
the preferred strategy in the surgical treatment of 
paroxysmal or non-paroxysmal AF in this population. 
More specifically, patients with an ASD and a his-
tory of AF (paroxysmal or non-paroxysmal) appear 
to benefit from concomitant biatrial arrhythmia sur-
gery during ASD repair. Although evidence is limited, 
the right-sided maze procedure is likely the most 
appropriate treatment of MRAT without documented 
AF, also because there is no evidence for superior-
ity of biatrial lesions in this situation. To date, there 
is not enough data to support the use of exclusive 
left-sided lesions in patients with CHD. CHD-specific 
outcomes were not only provided for ASD, but also 
for Ebstein anomaly and tetralogy of Fallot, although 
the amount of data was limited. It may however be 
reasonable to assume that the conclusions stated 
above also apply to these lesions, as they are as-
sociated with predominantly right-sided disease and 
outcomes of arrhythmia surgery were not vastly dif-
ferent from those in patients with ASD. As none of 
the studies compared outcomes of different energy 
sources, we cannot provide specific recommenda-
tions on the type of energy sources to be used for 
creation of lesions in this population.
Arrhythmia Surgery Techniques
In 1998, the right-sided maze procedure was pro-
posed for patients with right-sided CHD, after sev-
eral reports had published their experience with 
exclusive left-sided lesions.50 It was assumed that 
the left atrium was relatively unaffected in patients 
with right-sided CHD. Limiting the creation of lesions 
to the supposedly affected atrium resulted in a sig-
nificant simplification and shortening of the original 
Figure 4. Permanent pacemaker implantation.
Forest plot of the proportions of patients with permanent pacemaker implantation and corresponding 95% CIs. The overall median 
and interquartile range of proportions are displayed in red. IQR indicates interquartile range; and SND, sinus node dysfunction. 
*Indication for permanent pacemaker implantation. †Including intraoperatively implanted pacemakers. ‡Indication only provided for 
the 8 early pacemaker implantations. §Separate outcomes only available in sub-analysis at 1-year follow-up. ||Follow-up not specified 
for subgroup.
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procedure, with a lower risk of complications.43,50 
However, also in 1998, Kobayashi et al disputed the 
efficacy of exclusive right-sided lesions compared 
with biatrial lesions in the treatment of AF in patients 
with ASD.30 Years later, Im et al confirmed in a larger 
cohort of patients with ASD who exclusive right-
sided lesions were less effective in the treatment of 
AF than biatrial lesions.26 These results indicate that 
the left atrium may contribute at least in part to the 
substrate of AF in these patients, even if their CHD is 
predominantly right-sided.
In line with these observations, most studies in this 
review performed biatrial arrhythmia surgery for par-
oxysmal or non-paroxysmal AF. The median reported 
number of arrhythmia recurrences after biatrial ar-
rhythmia surgery was 13% (IQR, 0%–27%) in all stud-
ies and 20% (IQR, 11%–39%) in studies with sample 
size >20. The type of preoperative AF did not appear 
to affect late success, although this was only reported 
by one study in this review.40 Extensive variations in 
follow-up durations and surgical techniques limit the 
ability to comment on the efficacy of this procedure 
in the CHD population relative to that in a general AF 
population without CHD (7% after 1  year, 22% after 
5 years; no difference between types of AF).52
Although the right-sided maze is not as effective 
as the biatrial maze for treatment of AF, it is likely the 
most appropriate treatment strategy in patients with 
MRAT (without prior documented AF). From a mech-
anistic point of view, this can be explained by the 
fact that most MRATs are located in the right atrium, 
which is subject to longstanding pressure or volume 
overload and, often, surgical scarring.53 One study in-
cluded in this review reported no recurrences during 
a median follow-up of 2  years after right-sided ar-
rhythmia surgery for MRAT.43 Importantly, not 1 study 
provided evidence in favor of performing biatrial ar-
rhythmia surgery for MRAT. There were no studies 
specifically investigating the effect of duration of pre-
operative MRAT (paroxysmal versus non-paroxys-
mal) on the outcomes of arrhythmia surgery. Stulak 
et al indicate that they would favor biatrial lesions 
over right-sided lesions in case of “longer-standing 
arrhythmias”, although they did not differentiate be-
tween AF and MRAT in this recommendation nor in 
their results.44
Since only few studies included in this review (5/28) 
performed exclusive left-sided arrhythmia surgery in a 
small subset of patients without providing separate 
outcomes, we cannot form a solid conclusion on this 
matter. However, prior studies on a more general sur-
gical population demonstrated the superiority of bi-
atrial lesions over left atrial lesions only, particularly in 
case of persistent AF.54,55 In turn, a complete left atrial 
lesion set—generally consisting of pulmonary vein iso-
lation, connecting lesions to the mitral valve annulus 
and the left atrial appendage, and excision of the left 
atrial appendage—has also been shown to be more 
effective than pulmonary vein isolation alone.56,57
Energy Sources
The complexity of arrhythmia surgery has decreased 
somewhat because of the emergence of alternative 
energy sources replacing the cut-and-sew lesions 
of the original Cox Maze III procedure.26 However, 
in contrast to the cut-and-sew technique, continu-
ity and transmurality of lesions created by alternative 
energy sources may be incomplete.58 Various energy 
sources have been applied in the studies in this re-
view, although none provided separate outcomes. 
Radiofrequency ablation was the most commonly 
applied method in the more recent studies (>2008). 
A large systematic review by Khargi et al including 
48 studies and 3832 patients compared outcomes 
of surgical AF ablation using either the cut-and-sew 
technique or alternative energy sources.58 There was 
no difference in freedom from AF between the 2 
groups. As patients with CHD often have thickened 
and scarred myocardium, the risk of incomplete le-
sions when using alternative sources may still be rel-
evant in this specific population. To minimize this risk, 
irrigated radiofrequency may be used. Cooling of the 
catheter tip allows for higher power levels and hence 
the ability to create larger and deeper lesions.59 A 
recent study of Ad et al demonstrated the superi-
ority of cryothermal energy over radiofrequency en-
ergy, particularly in patients with larger left atrial size 
and longer AF duration.60 Of note, the successful use 
of cryothermal energy is dependent on tissue thick-
ness, requiring multiple freezes to obtain complete 
lesions in thicker target tissue.
Prophylactic Arrhythmia Surgery
The 2014 PACES/HRS guidelines and a 2018 position 
paper by the European Heart Rhythm Association 
(EHRA)/Association for European Paediatric and 
Congenital Cardiology (AEPC)/European Society of 
Cardiology (ESC) recommend that prophylactic ar-
rhythmia surgery may be considered in certain situa-
tions (patients with Ebstein anomaly or atrial dilatation 
undergoing surgery, patients with CHD undergoing 
re-operation).11,12 However, these recommendations 
were based on expert opinion or extrapolated from 
studies on therapeutic arrhythmia surgery in patients 
with CHD or prophylactic arrhythmia surgery in pa-
tients with non-congenital mitral valve disease. Our 
extensive literature search only identified 4 stud-
ies describing outcomes of prophylactic arrhythmia 
surgery in only a small number of patients. The only 
randomized controlled trial included in this review 
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was not able to draw conclusions on the efficacy 
of a prophylactic lesion during the lateral tunnel 
Fontan procedure, given the lack of occurrence of 
the primary end point in both the intervention and 
the control group. Another study applied prophylac-
tic right-sided lesions in most patients, which were 
not standardized and may have varied from patient to 
patient.23 Postoperative occurrences of MRAT (either 
spontaneous or induced) were observed in 2 stud-
ies, in which a prophylactic lesion between the right 
atriotomy and the right atrioventricular valve annulus 
was applied using cryoenergy.33,35 In 1 of these stud-
ies, the authors confirmed that these arrhythmias 
were caused by incomplete cryolesions.35 Similar 
observations were described in a study reporting 
characteristics of new-onset ATA after catheter abla-
tion of AF in a mixed population.61 In this study, nearly 
all ATA were related to gaps in prior ablation lines. As 
prophylactic arrhythmia surgery is performed without 
knowing if the patient will ever develop atrial arrhyth-
mias, the development of arrhythmias attributable 
to incomplete lesions is an extremely undesirable 
outcome. Although prophylactic arrhythmia surgery 
may be beneficial for patients with CHD with specific 
anatomic substrates predisposing them to the devel-
opment of ATA, it is yet unknown which lesion sets 
should be applied and which energy sources should 
be used. Based on the 4 studies that we identified in 
our literature search, we are unable to provide rec-
ommendations on specific surgical techniques for 
this matter. This indicates the need for studies in-
vestigating the outcomes of prophylactic arrhythmia 
in patients with CHD; ideally these are randomized 
studies with a sufficient sample size and follow-up 
duration following a standardized approach. This 
was also acknowledged by Mavroudis et al, who 
suggested prophylactic lesion sets to be used in 
standardized experimental protocols.62
Permanent Pacemaker Implantation
Twenty of the studies included in this review reported 
numbers of patients requiring permanent pacemaker 
implantation varying between 0% and 42%. Apart from 
those implanted in the context of Fontan conversion, 
the most common indication for pacemaker implanta-
tion was SND. It is widely recognized that permanent 
pacemaker implantation for SND is a potential adverse 
outcome of atrial arrhythmia surgery.63 Underlying SND 
may be unmasked once the ATA is successfully abol-
ished.64 Furthermore, injury to the sinoatrial node or its 
arteries may cause postoperative SND, although this is 
less likely to occur because of technical improvements 
and increased experience over the years.63,65
The wide range in reported numbers of pacemaker 
implantations may be because of the fact that policies 
differ between centers, for example on the indications for 
intraoperative pacemaker implantation. Furthermore, 
policies may have changed over the years as experi-
ence with arrhythmia surgery has evolved. Whereas in 
earlier years, early postoperative junctional rhythm may 
have been an indication for pacemaker implantation, 
experience has shown that stable sinus rhythm returns 
in many of these patients.63,65 In addition, the number 
of pacemaker implantations in some studies included 
those implanted as a part of the Fontan conversion 
procedure. For these reasons, and given the large het-
erogeneity in follow-up durations, study populations 
and arrhythmia surgery techniques, it is not possible to 
draw conclusions on whether pacemaker implantation 
in patients with CHD is more often required than in the 
general population (around 10%).65
Strengths and Limitations at Study and 
Outcome Level
Except for some of the more recent studies, sam-
ple sizes were relatively small, as is often the case in 
studies involving patients with CHD. Similar to studies 
evaluating the outcomes of endovascular AF ablation in 
patients with CHD,66 ASD was the predominant CHD 
type in most studies. Study designs were non-rand-
omized and mostly retrospective in nature. Despite limi-
tations generally associated with these designs, overall 
quality of the studies was acceptable. In some studies, 
patients with CHD were a subset of a larger group of 
patients not included in this review. As a result, more 
detailed information beyond the number of patients with 
an arrhythmia recurrence was often not provided (eg, 
outcomes according to lesion set or CHD type, pace-
maker implantation). Although most studies reported 
the number of arrhythmia recurrences, a considerable 
number of studies (n=10) did not differentiate between 
recurrence versus new-onset ATA, and 1 study re-
ported outcomes as recurrence or use of anti-arrhyth-
mic drugs. Data on the use of perioperative AAD were 
relatively scarce and heterogeneous, thereby limiting 
the ability to provide solid conclusions on the possible 
influence of AAD on outcomes of arrhythmia surgery in 
this population. Furthermore, indications for permanent 
pacemaker implantation were not always provided. The 
number of pacemaker implantations in some studies in-
cluded those implanted intraoperatively, which may be 
attributable to a variety of indications other than those 
directly related to arrhythmia surgery.
The large variation in follow-up durations among the 
included studies complicates the interpretation of out-
comes, particularly since most studies did not report 
yearly event rates or the number of recurrences at fixed 
time points (eg 1 year, 5 years). It may be reasonable 
to expect that the duration of follow-up is related to the 
number of arrhythmia recurrences. We chose not to 
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calculate yearly event rates, because we did not have 
individual study data at our disposal. Also, since the 
distribution of follow-up duration appeared skewed in 
many studies, extrapolation to rates merely based on 
presented number of recurrences and mean or median 
follow-up duration may potentially have led to incor-
rect results. This limited our options for performing a 
meaningful meta-analysis. In addition, the proportion 
of arrhythmia recurrence in a considerable number of 
studies was 0 or 1; small sample size contributed to 
this. For inclusion in a meta-analysis, corrections that 
account for such proportions would have to be made, 
with arguable consequences for the results. Finally, 
even after dividing results into relevant subcategories, 
significant heterogeneity remained regarding study 
populations, definitions of outcome measures and 
variations in lesion sets and energy sources. For these 
reasons, we deemed a meta-analysis unable to provide 
meaningful results here and chose to refrain from it.
Strengths and Limitations at Review Level
This review was conducted according to the PRISMA 
guidelines, thereby providing transparency of the 
methods and a systematic and uniform approach 
to answering our primary research question.15 We 
included studies from many different countries and 
centers, which broadens the perspective on the one 
hand, but is accompanied by various levels of ex-
pertise, patients volumes, and center-specific poli-
cies on the other hand, which should be considered 
when interpreting the results. We did not set a start 
date restriction for the literature search, as there was 
no concrete evidence on the basis of which a spe-
cific year or time period should have been selected. 
Furthermore, this approach resulted in a complete 
overview of the evolution of atrial arrhythmia sur-
gery in patients with CHD. Inevitably, this decision 
in itself causes heterogeneity among studies, given 
the changes in surgical techniques over the years. 
Only studies written in the English language were in-
cluded, which may have led to the exclusion of po-
tentially relevant studies. We decided not to exclude 
studies including also patients undergoing Fontan 
conversion, as this would often have led to the ex-
clusion of a substantial number of other patients rel-
evant to the primary research question. Instead, by 
setting specific inclusion criteria (ie, <25% of patients 
undergoing Fontan conversion) we limited the influ-
ence of these patients on the outcomes.
CONCLUSIONS
This systematic review summarized outcomes of 
atrial arrhythmia surgery in patients with CHD pub-
lished over a time span of 25 years. Regardless of the 
many variations in indications, surgical techniques, 
and follow-up durations, this review reports a median 
arrhythmia recurrence of 13% (IQR, 4%–26%). More 
specifically, based on the acquired data, biatrial le-
sions are preferred in the treatment of AF, whereas ex-
clusive right-sided lesions may be more appropriate in 
the treatment of MRAT. To date, it is unclear whether 
the addition of left-sided lesions would be beneficial 
to the treatment of MRAT. Theoretically, prophylactic 
atrial arrhythmia surgery may be beneficial in this pop-
ulation, but evidence is currently limited. To be able to 
provide more specific recommendations, future stud-
ies should specifically report outcomes according to 
the type of preoperative arrhythmia, underlying CHD, 
lesion set, and energy source, as this is essential for 
determining which surgical technique should ideally 
be applied under which circumstances. Additionally, 
differentiation between recurrence and new-onset 
regular ATA should be made and indications for pace-
maker implantation clearly described, to be able to as-
sess potential adverse outcomes.
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Data S1. 
 
Complete search strategy  
 
Date of search: 20-11-2019 
 
Outcomes of atrial arrhythmia surgery in patients with congenital heart disease. 
 
Database searched via Years of 
coverage 
References After de-
duplication 
Embase  Embase.com 1971 - Present 1594 1573 
Medline ALL  Ovid  1946 - Present 1454 326 
Web of Science Core 
Collection  
Web of 
Knowledge  
1975 - Present 842 121 
Cochrane Central Register of 
Controlled Trials 
Wiley  1992 - Present 90 61 
Other sources: Google Scholar 200 93 
Total 4180 2174 
 
Embase, 1594 
('congenital heart disease'/de OR 'congenital heart malformation'/exp OR (fontan* OR 
((triatr* OR dextro*) NEAR/3 (cor* OR heart* OR cardiac*)) OR dextrocard* OR ebstein* 
OR fallot* OR ((congen* Or anomal* OR malform* OR defect*) NEAR/12 (heart* OR 
septa* OR septum* OR ventricle*)) OR ((heart*) NEAR/6 (shunt* OR hypoplastic*) 
NEAR/6 (left OR right))):ab,ti,kw) AND ('maze procedure'/de OR 'maze surgery'/de OR 'cox 
maze procedure'/de OR (('supraventricular tachycardia' OR 'reentry tachycardia'/exp OR 
'atrial fibrillation'/exp OR 'reentry arrhythmia'/de OR 'heart atrium arrhythmia'/exp) AND 
('ablation therapy'/exp) AND ('Fontan procedure'/exp OR 'surgery'/de OR 'heart surgery'/exp 
OR 'cryosurgery'/de)) OR (((surger* OR surgi* OR fontan) NEAR/8 (tachyarrhythm* OR 
dysrhythm* OR disrhythm* OR flutter* OR tachycardi* OR fibrillation* OR arrhythm*)) 
OR maze*):ab,ti,kw) NOT ([Conference Abstract]/lim) NOT ([animals]/lim NOT 
[humans]/lim) 
 
Medline(Ovid), 1454 
(exp "Heart Defects, Congenital"/ OR (fontan* OR ((triatr* OR dextro*) ADJ3 (cor* OR 
heart* OR cardiac*)) OR dextrocard* OR ebstein* OR fallot* OR ((congen* Or anomal* OR 
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malform* OR defect*) ADJ12 (heart* OR septa* OR septum* OR ventricle*)) OR ((heart*) 
ADJ6 (shunt* OR hypoplastic*) ADJ6 (left OR right))).ab,ti,kw.) AND (((exp "Tachycardia, 
Supraventricular"/ OR "Atrial Fibrillation"/ OR "Atrial Flutter"/) AND ("Ablation 
Techniques"/) AND ("Fontan Procedure"/ OR exp "Surgical Procedures, Operative"/ OR 
"Thoracic Surgery"/ OR "Cryosurgery"/)) OR (((surger* OR surgi* OR fontan) ADJ8 
(tachyarrhythm* OR dysrhythm* OR disrhythm* OR flutter* OR tachycardi* OR 
fibrillation* OR arrhythm*)) OR maze*).ab,ti,kw.) NOT (news OR congres* OR abstract* 
OR book* OR chapter* OR dissertation abstract*).pt. NOT (exp animals/ NOT humans/) 
 
Web-of-Science Core Collection, 842 
TS=(((fontan* OR ((triatr* OR dextro*) NEAR/2 (cor* OR heart* OR cardiac*)) OR 
dextrocard* OR ebstein* OR fallot* OR ((congen* Or anomal* OR malform* OR defect*) 
NEAR/12 (heart* OR septa* OR septum* OR ventricle*)) OR ((heart*) NEAR/5 (shunt* OR 
hypoplastic*) NEAR/5 (left OR right)))) AND (((surger* OR surgi* OR fontan) NEAR/8 
(tachyarrhythm* OR dysrhythm* OR disrhythm* OR flutter* OR tachycardi* OR 
fibrillation* OR arrhythm*)) OR maze*) NOT ((animal* OR rat OR rats OR mouse OR mice 
OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR 
cows OR bovine OR rodent* OR sheep OR ovine OR pig OR swine OR porcine OR 
veterinar* OR chick* OR zebrafish* OR baboon* OR nonhuman* OR primate* OR cattle* 
OR goose OR geese OR duck OR macaque* OR avian* OR bird* OR fish*) NOT (human* 
OR patient* OR women OR woman OR men OR man))) AND DT=(article OR review) 
 
Cochrane, 90 (1 cochrane review, trials 89) 
((fontan* OR ((triatr* OR dextro*) NEAR/3 (cor* OR heart* OR cardiac*)) OR dextrocard* 
OR ebstein* OR fallot* OR ((congen* Or anomal* OR malform* OR defect*) NEAR/12 
(heart* OR septa* OR septum* OR ventricle*)) OR ((heart*) NEAR/6 (shunt* OR 
hypoplastic*) NEAR/6 (left OR right))):ab,ti,kw) AND ((((surger* OR surgi* OR fontan) 
NEAR/8 (tachyarrhythm* OR dysrhythm* OR disrhythm* OR flutter* OR tachycardi* OR 
fibrillation* OR arrhythm*)) OR maze*):ab,ti,kw) 
 
Google Scholar, 200 
"congenital heart disease" arrhythmia|arrhythmias surgery|surgical 
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